Deal Watch: AstraZeneca Buys, Sells And Partners In Busy Week
Executive Summary
In frenetic week, AstraZeneca signs PD-L1 combo study pact, buys data-analysis firm and divests generalized lipodystrophy drug to Aegerion to focus pipeline efforts on core areas. Merck becomes the latest big pharma to sign on with Bind, and Astellas and Proteostasis agree to an R&D collaboration in unfolded protein response.
You may also be interested in...
Pharmacyclics/Janssen Offer Suite Of Patient Support Programs For Imbruvica
With a monthly cost of $10,900/month for the ultra-rare disease mantle cell lymphoma, Pharmacyclics and Janssen are being proactive about patient aid with a 30-day offer while reimbursement is worked out, as well as other support offerings that have become part of the new reality for high-priced oncologics.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.